Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma

por Fields, R C, Strong, V E, Gönen, M, Goodman, K A, Rizk, N P, Kelsen, D P, Ilson, D H, Tang, L H, Brennan, M F, Coit, D G, Shah, M A
Publicado 2011

Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis

por Wu, T, Giovannucci, E, Welge, J, Mallick, P, Tang, W-Y, Ho, S-M
Publicado 2011

Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates

por Møller, H, Richards, S, Hanchett, N, Riaz, S P, Lüchtenborg, M, Holmberg, L, Robinson, D
Publicado 2011

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

por Cassidy, J, Clarke, S, Díaz-Rubio, E, Scheithauer, W, Figer, A, Wong, R, Koski, S, Rittweger, K, Gilberg, F, Saltz, L
Publicado 2011

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

por Marcuello, E, Páez, D, Paré, L, Salazar, J, Sebio, A, del Rio, E, Baiget, M
Publicado 2011

Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030

por Lin, L, Liu, Y, Li, H, Li, P-K, Fuchs, J, Shibata, H, Iwabuchi, Y, Lin, J
Publicado 2011

The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma

por den Hoed, C M, van Blankenstein, M, Dees, J, Kuipers, E J
Publicado 2011

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma

por Buechner, J, Tømte, E, Haug, B H, Henriksen, J R, Løkke, C, Flægstad, T, Einvik, C
Publicado 2011

Epstein–Barr virus microRNAs and lung cancer

por Koshiol, J, Gulley, M L, Zhao, Y, Rubagotti, M, Marincola, F M, Rotunno, M, Tang, W, Bergen, A W, Bertazzi, P A, Roy, D, Pesatori, A C, Linnoila, I, Dittmer, D, Goldstein, A M, Caporaso, N E, McShane, L M, Wang, E, Landi, M T
Publicado 2011

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53

por Millar, E K A, Graham, P H, McNeil, C M, Browne, L, O'Toole, S A, Boulghourjian, A, Kearsley, J H, Papadatos, G, Delaney, G, Fox, C, Nasser, E, Capp, A, Sutherland, R L
Publicado 2011

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma

por Liles, J S, Arnoletti, J P, Kossenkov, A V, Mikhaylina, A, Frost, A R, Kulesza, P, Heslin, M J, Frolov, A
Publicado 2011

Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study

por Lind, H, Waldenström, A-C, Dunberger, G, al-Abany, M, Alevronta, E, Johansson, K-A, Olsson, C, Nyberg, T, Wilderäng, U, Steineck, G, Åvall-Lundqvist, E
Publicado 2011

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target

por Iida, K, Nakayama, K, Rahman, M T, Rahman, M, Ishikawa, M, Katagiri, A, Yeasmin, S, Otsuki, Y, Kobayashi, H, Nakayama, S, Miyazaki, K
Publicado 2011

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

por Peasland, A, Wang, L-Z, Rowling, E, Kyle, S, Chen, T, Hopkins, A, Cliby, W A, Sarkaria, J, Beale, G, Edmondson, R J, Curtin, N J
Publicado 2011

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

por Lee, C K, Gurney, H, Brown, C, Sorio, R, Donadello, N, Tulunay, G, Meier, W, Bacon, M, Maenpaa, J, Petru, E, Reed, N, Gebski, V, Pujade-Lauraine, E, Lord, S, Simes, R J, Friedlander, M
Publicado 2011

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

por Ladoire, S, Arnould, L, Mignot, G, Apetoh, L, Rébé, C, Martin, F, Fumoleau, P, Coudert, B, Ghiringhelli, F
Publicado 2011

Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours

por Kosmas, C, Vorgias, G, Tsakonas, G, Politis, P, Daladimos, T, Panagiotidi, E, Papachrysanthou, T, Moschovis, D, Kalinoglou, N, Tsavaris, N, Karabelis, A, Mylonakis, N
Publicado 2011

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

por Zang, R Y, Harter, P, Chi, D S, Sehouli, J, Jiang, R, Tropé, C G, Ayhan, A, Cormio, G, Xing, Y, Wollschlaeger, K M, Braicu, E I, Rabbitt, C A, Oksefjell, H, Tian, W J, Fotopoulou, C, Pfisterer, J, du Bois, A, Berek, J S
Publicado 2011

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

por Raja, F A, Griffin, C L, Qian, W, Hirte, H, Parmar, M K, Swart, A M, Ledermann, J A
Publicado 2011

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells

por Sudhagar, S, Sathya, S, Lakshmi, B S
Publicado 2011